A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary) ; Tocilizumab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms ELARA
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 19 Nov 2019 Planned End Date changed from 24 Aug 2022 to 25 Aug 2022.
- 19 Nov 2019 Planned primary completion date changed from 19 Feb 2021 to 22 Feb 2021.
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology